2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.
Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.
It is important to develop tools to predict how patients are going to react to treatments, explains Stephenson. This can help the patient’s quality of life and equip them with the knowledge to make a well-informed decision regarding their treatment. Additionally, this can lead to higher rates of patient satisfaction, states Stephenson.
Related Content: